25 Nov

Pre-quotation disclosure statement

Biome Australia Limited ABN: 51 627 364 014 16 Dover Street, Cremorne VIC 3121 +61 3 9017 5800 | www.biomeaustralia.com FOR IMMEDIATE RELEASE Satisfaction of Listing Conditions Melbourne, Victoria, 30 November 2021 – complementary medicines company , Biome Australia Limited ( Biome Australia ) confirms that it has satisfied each of the Conditions to Admission as detailed in the Admission Decision dated 18 November 2021. Biome Australia provides the following pre-quotation disclosures: 2 The conversion of Performance Rights and issue of Options The issue of the following securities: Securities Detail Number Ordinary Shares The 11,175,907 Performance Rights have been converted into 11,175,907 Ordinary Shares. 11,175,907 Ordinary Shares Options 2,131,404 options have been issued with an exercise price of $0.30 exercisable for a period of three years from the date of issue to a controlled entity of Canaccord Genuity (Australia) Limited 2,131,404 Options 2,131,404 options with an exercise price of $0.40 exercisable for a period of four years from the date of issue to a controlled entity of Canaccord Genuity (Australia) Limited 2,131,404 Options ASX imposed escrow The following Shares and Options are subject to ASX restrictions: Securit y Numbe r A SX restriction period Ordinary Shares 39,359,545 24 months commencing on the date of official quotation of the ordinary shares in Biome Australia Ordinary Shares 718,842 Ending on 11 January 2022 415,582 Ending on 1 March 2022 506,336 Ending on 12 March 2022 16,848 Ending on 19 March 2022 126,290 Ending on 26 March 2022 89,856 Ending on 29 March 2022 251,595 Ending on 26 April 2022 336,958 Ending on 13 May 2022 224,638 Ending on 1 June 2022 112,319 Ending on 11 June 2022 28,107 Ending on 15 June 2022 224,638 Ending on 16 June 2022 188,697 Ending on 18 June 2022 224,638 Ending on 21 June 2022 494,203 Ending on 22 June 2022 1,120,652 Ending on 23 June 2022 3 224,638 Ending on 28 June 2022 112,319 Ending on 30 June 2022 224,638 Ending on 19 July 2022 560,696 Ending on 20 July 2022 22,464 Ending on 26 July 2022 33,696 Ending on 27 July 2022 44,928 Ending on 29 July 2022 20,218 Ending on 30 July 2022 112,319 Ending on 4 August 2022 1,213,498 Ending on 5 August 2022 65,236 Ending on 6 August 2022 134,783 Ending on 9 August 2022 151,631 Ending on 10 August 2022 60,653 Ending on 11 August 2022 101,088 Ending on 12 August 2022 22,464 Ending on 13 August 2022 56,160 Ending on 15 August 2022 179,801 Ending on 16 August 2022 325,726 Ending on 18 August 2022 381,885 Ending on 31 August 2022 Options 4,401,865 24 months commencing on the date of official quotation of the ordinary shares in Biome Australia Voluntary escrow The following Shares are subject to voluntary escrow: Securit y Numbe r A SX restriction period Ordinary Shares 47,470,727 Ending 6 months following the date of quotation, being 31 May 2022 4 Biome Australia's capital deck The capital deck of Biome Australia is as follows: Securit y Numbe r Ordinary Shares 199,909,857 Ordinary Shares. This is made up of: ? 148,733,950 Existing Shares; ? 40,000,000 Shares issued under the Offer; and ? 11,175,907 Shares issued on conversion of Performance Rights. Options 17,261,659 Options. This is made up of: ? 12,998,851 Existing Options; and ? 4,262,808 Options issued to a controlled entity of the Lead Manager, Canaccord Genuity (Australia) Limited. Authorised for release by the Board of Biome Australia Limited. About Biome Australia Limited Biome Australia Biome Australia develops, licenses, commercialises innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all. Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics ® . Supported by clinical research, including randomised double-blind placebo-controlled trials , Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns. Biome also develops, licenses and distributes a scientifically formulated, organic nutraceutical range, Activated Nutrients ® and a sports performance and recovery range, Activated X Performance ® , which is made exclusively for professional athletes. For more information visit: www.biomeaustralia.com For further information, please contact: George Lazarou Company Secretary T: (03) 8617 8014 E: george@activated.co
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Biome Australia Limited (ASX:BIO) when you join Listcorp.